Clinical Trial

Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2

Study acronym: IRIS-2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is a randomized, double-blind, placebo-controlled clinical trial. Investigators aim to assess the efficacy and safety of interleukin-6 receptor inhibitor combined with endovascular treatment in patients with acute anterior circulation large vessel occlusion stroke.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-13
notable Primary completion moved earlier: 2027-03-01 -> 2026-09-16 2026-06-13
minor Completion moved earlier: 2027-03-01 -> 2026-09-16 2026-06-13
Trial Details
NCT Number NCT07263776
Lead Sponsor Capital Medical University
Conditions Acute Ischemic Stroke
Enrollment 692 participants
Start Date 2025-12-05
Primary Completion 2026-09-16 (estimated)
Study Completion 2026-09-16 (estimated)
Updated on ClinicalTrials.gov 2026-06-12